Ovarian Function of Nasopharyngeal Carcinoma Women Survivors

Sponsor
Sun Yat-sen University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05183724
Collaborator
(none)
602
1
48
12.5

Study Details

Study Description

Brief Summary

This is an observational cohort study aimed to explore the fertility concerns, fertility preservation strategies, fertility status (pregnancy and Ovarian Failure) and birth outcome among young woman Nasopharyngeal carcinoma patients.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    The purpose of this study was to explore the effects of radiotherapy and chemotherapy on ovarian function and pregnancy outcome after treatment in female survivors of non-metastatic nasopharyngeal carcinoma, so as to clarify the relationship between ovarian dysfunction after treatment and pregnancy outcome, as well as clarify the relationship between pregnancy after treatment and tumour progression.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    602 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Effects of Radiotherapy and Chemotherapy on Ovarian Function and Post-treatment Pregnancy Outcomes in Women With Nasopharyngeal Carcinoma
    Anticipated Study Start Date :
    Jan 10, 2022
    Anticipated Primary Completion Date :
    Jan 10, 2025
    Anticipated Study Completion Date :
    Jan 10, 2026

    Outcome Measures

    Primary Outcome Measures

    1. Premature Ovarian Failure (POF) [3 years after Radiotherapy]

      Premature Ovarian Failure (POF) was defined as menopause before age 40 years. Menopause was defined as cessation of menstruation at least 1 year before the date of the survey in the absence of pregnancy, breastfeeding, continuous use of progestagens or other medication causing amenorrhea, or surgical removal of uterus and/ or ovaries.

    Secondary Outcome Measures

    1. Progress-Free Survival (PFS) [3 years after Radiotherapy]

      Progress-free survival is calculated from the date of registration to the date of the first progress at any site.

    2. Pregnancy and birth outcome [Within 6 month of diagnosis, or 3-5years after Radiotherapy]

      The pregnancy history and pregnancy outcome of female Nasopharyngeal carcinoma (NPC) patients before diagnosis of NPC would be investigate Within 6 months of diagnosis. The pregnancy events and birth outcome of female NPC patients after diagnosis of NPC would be investigate among 3 to 5years after Radiotherapy.

    3. Overall Survival (OS) [3 years after Radiotherapy]

      The Overall Survival (OS) was defined as the duration from the date of registration assignment to the date of death from any cause or censored at the date of the last follow-up.

    4. Locoregional Relapse-Free Survival (LRFS) [3 years after Radiotherapy]

      The Locoregional Relapse-Free Survival (LRFS) is evaluated and calculated from the date of registration until the day of first locoregional relapse or until the date of the last follow-up visit

    5. Distant Metastasis-Free Survival (DMFS) [3 years after Radiotherapy]

      The DMFS is evaluated and calculated from the date of registration until the day of first distant metastases or until the date of the last follow-up visit.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 45 Years
    Sexes Eligible for Study:
    Female
    Inclusion Criteria:
    1. Patients with newly histologically confirmed non-keratinizing nasopharyngeal carcinoma, including WHO II or III ,with no distant metastasis

    2. Age between 18-45, female

    3. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1

    4. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×upper limit of normal (ULN),serum total bilirubin (TBIL) ≤2.0 times the upper limit of normal (ULN) .

    5. Adequate renal function: creatinine clearance rate≥60 ml/min or Creatinine ≤1.5× upper limit of normal value.

    6. No history of infertility.

    7. No history of hysterectomy or bilateral ovariectomy.

    8. Patient have signed on the informed consent, and well understood the objective and procedure of this study

    Exclusion Criteria:
    1. Histologically or cytologically confirmed with keratinizing squamous cell carcinoma of the nasopharynx.

    2. Women in the period of pregnancy, lactation, or reproductive without effective contraceptive measures.

    3. Known history of other malignancies (except cured basal cell carcinoma or carcinoma in situ of the cervix).

    4. Patients with severe dysfunction of heart, liver, lung, kidney or marrow.

    5. Patients with severe, uncontrolled disease or infections.

    6. Refuse or fail to sign the informed consent .

    7. Patients with personality or mental disorders, incapacity or limited capacity for civil conduct.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center Guangzhou Guangdong China 510060

    Sponsors and Collaborators

    • Sun Yat-sen University

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Hai-Qiang Mai,MD,PhD, Chief Physician, Sun Yat-sen University
    ClinicalTrials.gov Identifier:
    NCT05183724
    Other Study ID Numbers:
    • Ovarian Function of NPC
    First Posted:
    Jan 11, 2022
    Last Update Posted:
    Jan 11, 2022
    Last Verified:
    Jan 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Hai-Qiang Mai,MD,PhD, Chief Physician, Sun Yat-sen University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jan 11, 2022